NASDAQ:IDYA IDEAYA Biosciences (IDYA) Stock Price, News & Analysis $35.82 +0.37 (+1.06%) As of 10:08 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About IDEAYA Biosciences Stock (NASDAQ:IDYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IDEAYA Biosciences alerts:Sign Up Key Stats Today's Range$35.47▼$36.1750-Day Range$27.60▼$40.5152-Week Range$21.50▼$40.58Volume29,645 shsAverage Volume1.13 million shsMarket Capitalization$3.15 billionP/E RatioN/ADividend YieldN/APrice Target$50.25Consensus RatingModerate Buy Company Overview IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications. Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies. This platform supports the rapid progression of drug candidates from target validation through early clinical development. IDEAYA has entered strategic collaborations with established pharmaceutical partners to expand the reach of its synthetic lethality portfolio, leveraging complementary expertise in drug discovery, development, and commercialization. Founded in 2016 and headquartered in South San Francisco, California, IDEAYA maintains research operations in the United States and collaborates with leading academic institutions and industry organizations worldwide. The company’s management team comprises experienced biopharmaceutical executives and oncology researchers who guide its mission to deliver precision medicines to patients with high-need cancers. IDEAYA continues to build on its scientific foundation to bring forward innovative treatments that address genetically defined subsets of tumors.AI Generated. May Contain Errors. Read More IDEAYA Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreIDYA MarketRank™: IDEAYA Biosciences scored higher than 69% of companies evaluated by MarketBeat, and ranked 251st out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 15 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialIDEAYA Biosciences has a consensus price target of $50.25, representing about 41.7% upside from its current price of $35.45.Amount of Analyst CoverageIDEAYA Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IDEAYA Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for IDEAYA Biosciences are expected to grow in the coming year, from ($4.10) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -22.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -22.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IDEAYA Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.34% of the float of IDEAYA Biosciences has been sold short.Short Interest Ratio / Days to CoverIDEAYA Biosciences has a short interest ratio ("days to cover") of 6.08.Change versus previous monthShort interest in IDEAYA Biosciences has recently decreased by 2.77%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.29 News SentimentIDEAYA Biosciences has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for IDEAYA Biosciences this week, compared to 5 articles on an average week.Search Interest4 people have searched for IDYA on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $382,096.00 in company stock.Percentage Held by Insiders4.70% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IDEAYA Biosciences' insider trading history. Receive IDYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDYA Stock News HeadlinesIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 21 at 2:14 AM | americanbankingnews.comIDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical ProgramsJuly 17, 2026 | prnewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 21 at 1:00 AM | Porter & Company (Ad)IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA FilingJuly 16, 2026 | theglobeandmail.comIDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology SummitJuly 15, 2026 | theglobeandmail.comIDEAYA Biosciences Analyst Ratings and Price Targets | NASDAQ:IDYA | BenzingaJuly 14, 2026 | benzinga.comIDEAYA Biosciences (NASDAQ:IDYA) CAO Sells $382,095.50 in StockJuly 12, 2026 | americanbankingnews.comInsider Selling: IDEAYA Biosciences (NASDAQ:IDYA) CAO Sells $382,095.50 in StockJuly 10, 2026 | insidertrades.comSee More Headlines IDYA Stock Analysis - Frequently Asked Questions How have IDYA shares performed this year? IDEAYA Biosciences' stock was trading at $34.57 at the beginning of 2026. Since then, IDYA shares have increased by 2.5% and is now trading at $35.45. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its earnings results on Tuesday, May, 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by $0.04. The firm's revenue was down 39.4% compared to the same quarter last year. When did IDEAYA Biosciences IPO? IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO. Who are IDEAYA Biosciences' major shareholders? IDEAYA Biosciences' top institutional shareholders include Tema ETFs LLC (0.15%), Handelsbanken Fonder AB (0.04%) and Versant Capital Management Inc. Insiders that own company stock include Yujiro S Hata, Jeffrey Stein, Briseno Andres Ruiz, Paul A Stone, Michael Anthony White and Jason Throne. View institutional ownership trends. How do I buy shares of IDEAYA Biosciences? Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW). Company Calendar Last Earnings5/05/2026Today7/21/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 IDYA's financial health is in the Green zone, according to TradeSmith. IDYA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IDYA CIK1676725 Webwww.ideayabio.com Phone(650) 443-6209FaxN/AEmployees80Year Founded2015Price Target and Rating Average Price Target for IDEAYA Biosciences$50.25 High Price Target$79.00 Low Price Target$30.00 Potential Upside/Downside+40.1%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$113.70 million Net MarginsN/A Pretax Margin-62.17% Return on Equity-14.24% Return on Assets-13.09% Debt Debt-to-Equity RatioN/A Current Ratio10.74 Quick Ratio10.74 Sales & Book Value Annual Sales$218.71 million Price / Sales14.40 Cash FlowN/A Price / Cash FlowN/A Book Value$11.67 per share Price / Book3.07Miscellaneous Outstanding Shares87,860,000Free Float83,732,000Market Cap$3.15 billion OptionableOptionable Beta-0.09 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:IDYA) was last updated on 7/21/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDYA Stock Alerts